Which has preferable valuation & earnings, AZN or GSK?

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AstraZeneca £61.37B 3.09 £8.71B £668.00 18.32 GSK £33.20B 2.31 £2.50B £117.80 16.29

Is AZN or GSK more profitable?

AstraZeneca has a net margin of 17.02% compared to GSK's net margin of 14.52%. GSK's return on equity of 28.35% beat AstraZeneca's return on equity. Company Net Margins Return on Equity Return on Assets AstraZeneca 17.02% 21.68% 7.68% GSK 14.52% 28.35% 9.56%

Does the media refer more to AZN or GSK?

In the previous week, AstraZeneca had 3 more articles in the media than GSK. MarketBeat recorded 8 mentions for AstraZeneca and 5 mentions for GSK. GSK's average media sentiment score of 0.39 beat AstraZeneca's score of -0.31 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AstraZeneca 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral GSK 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GSK or BMK?

GSK presently has a consensus target price of GBX 2,048.57, indicating a potential upside of 6.78%. Given GSK's stronger consensus rating and higher possible upside, research analysts clearly believe GSK is more favorable than Benchmark. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Benchmark 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, GSK or BMK?

GSK has higher revenue and earnings than Benchmark. GSK is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK £33.20B 2.31 £2.50B £117.80 16.29 Benchmark £79.16M 1,189.43 -£39.55M £0.06 246,774.19

Is GSK or BMK more profitable?

GSK has a net margin of 14.52% compared to Benchmark's net margin of -43.67%. GSK's return on equity of 28.35% beat Benchmark's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.52% 28.35% 9.56% Benchmark -43.67% -15.96% -1.07%

Does the media favor GSK or BMK?

In the previous week, GSK had 4 more articles in the media than Benchmark. MarketBeat recorded 5 mentions for GSK and 1 mentions for Benchmark. Benchmark's average media sentiment score of 0.67 beat GSK's score of 0.39 indicating that Benchmark is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Benchmark 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DPH or GSK?

GSK has a consensus price target of GBX 2,048.57, indicating a potential upside of 6.78%. Given GSK's stronger consensus rating and higher probable upside, analysts clearly believe GSK is more favorable than Dechra Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dechra Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GSK 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Which has higher earnings and valuation, DPH or GSK?

GSK has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dechra Pharmaceuticals £761.50M 0.00 -£27.90M -£0.25 N/A GSK £33.20B 2.31 £2.50B £117.80 16.29

Which has preferable earnings & valuation, HIK or GSK?

GSK has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hikma Pharmaceuticals £3.42B 1.00 £353.21M £181.00 9.04 GSK £33.20B 2.31 £2.50B £117.80 16.29

Does the media favor HIK or GSK?

In the previous week, GSK had 4 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 5 mentions for GSK and 1 mentions for Hikma Pharmaceuticals. Hikma Pharmaceuticals' average media sentiment score of 0.75 beat GSK's score of 0.39 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hikma Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GSK or INDV?

GSK currently has a consensus price target of GBX 2,048.57, indicating a potential upside of 6.78%. Given GSK's stronger consensus rating and higher possible upside, research analysts clearly believe GSK is more favorable than Indivior. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Indivior 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, GSK or INDV?

GSK has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK £33.20B 2.31 £2.50B £117.80 16.29 Indivior £1.40B 1.38 -£2.36M -£1.21 N/A

Is GSK or INDV more profitable?

GSK has a net margin of 14.52% compared to Indivior's net margin of 11.44%. GSK's return on equity of 28.35% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.52% 28.35% 9.56% Indivior 11.44% -23.90% 2.37%

Does the media prefer GSK or INDV?

In the previous week, GSK had 4 more articles in the media than Indivior. MarketBeat recorded 5 mentions for GSK and 1 mentions for Indivior. Indivior's average media sentiment score of 0.75 beat GSK's score of 0.39 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GSK (GSK) Competitors

GBX 1,918.50 -2.00 (-0.10%)

As of 08/21/2026 12:44 PM Eastern

Compare

GSK vs. AZN, BMK, DPH, HIK, and INDV

Should you buy GSK stock or one of its competitors? GSK's main competitors and comparable companies include AstraZeneca (AZN), Benchmark (BMK), Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), and Indivior (INDV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GSK compare to AstraZeneca?

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

AstraZeneca has a beta of 0.211, indicating that its stock price is 79% less volatile than the broader market. Comparatively, GSK has a beta of 0.295, indicating that its stock price is 71% less volatile than the broader market.

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£61.37B	3.09	£8.71B	£668.00	18.32
GSK	£33.20B	2.31	£2.50B	£117.80	16.29

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.6%. GSK pays an annual dividend of GBX 67 per share and has a dividend yield of 3.5%. AstraZeneca pays out 47.4% of its earnings in the form of a dividend. GSK pays out 56.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, AstraZeneca had 3 more articles in the media than GSK. MarketBeat recorded 8 mentions for AstraZeneca and 5 mentions for GSK. GSK's average media sentiment score of 0.39 beat AstraZeneca's score of -0.31 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
GSK	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AstraZeneca currently has a consensus price target of £152.17, suggesting a potential upside of 24.32%. GSK has a consensus price target of GBX 2,048.57, suggesting a potential upside of 6.78%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts clearly believe AstraZeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

AstraZeneca has a net margin of 17.02% compared to GSK's net margin of 14.52%. GSK's return on equity of 28.35% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.02%	21.68%	7.68%
GSK	14.52%	28.35%	9.56%

67.8% of AstraZeneca shares are held by institutional investors. Comparatively, 56.9% of GSK shares are held by institutional investors. 0.2% of AstraZeneca shares are held by company insiders. Comparatively, 0.2% of GSK shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

AstraZeneca beats GSK on 12 of the 18 factors compared between the two stocks.

How does GSK compare to Benchmark?

GSK (LON:GSK) and Benchmark (LON:BMK) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

GSK presently has a consensus target price of GBX 2,048.57, indicating a potential upside of 6.78%. Given GSK's stronger consensus rating and higher possible upside, research analysts clearly believe GSK is more favorable than Benchmark.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Benchmark	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

56.9% of GSK shares are held by institutional investors. Comparatively, 13.3% of Benchmark shares are held by institutional investors. 0.2% of GSK shares are held by insiders. Comparatively, 63.7% of Benchmark shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

GSK has higher revenue and earnings than Benchmark. GSK is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	£33.20B	2.31	£2.50B	£117.80	16.29
Benchmark	£79.16M	1,189.43	-£39.55M	£0.06	246,774.19

In the previous week, GSK had 4 more articles in the media than Benchmark. MarketBeat recorded 5 mentions for GSK and 1 mentions for Benchmark. Benchmark's average media sentiment score of 0.67 beat GSK's score of 0.39 indicating that Benchmark is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Benchmark	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has a beta of 0.295, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Benchmark has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

GSK has a net margin of 14.52% compared to Benchmark's net margin of -43.67%. GSK's return on equity of 28.35% beat Benchmark's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.52%	28.35%	9.56%
Benchmark	-43.67%	-15.96%	-1.07%

Summary

GSK beats Benchmark on 11 of the 16 factors compared between the two stocks.

How does GSK compare to Dechra Pharmaceuticals?

Dechra Pharmaceuticals (LON:DPH) and GSK (LON:GSK) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Dechra Pharmaceuticals has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, GSK has a beta of 0.295, indicating that its stock price is 71% less volatile than the broader market.

GSK has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A
GSK	£33.20B	2.31	£2.50B	£117.80	16.29

Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. GSK pays an annual dividend of GBX 67 per share and has a dividend yield of 3.5%. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. GSK pays out 56.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

105.5% of Dechra Pharmaceuticals shares are held by institutional investors. Comparatively, 56.9% of GSK shares are held by institutional investors. 9.3% of Dechra Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of GSK shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, GSK had 5 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 5 mentions for GSK and 0 mentions for Dechra Pharmaceuticals. GSK's average media sentiment score of 0.39 beat Dechra Pharmaceuticals' score of 0.00 indicating that GSK is being referred to more favorably in the news media.

Company	Overall Sentiment
Dechra Pharmaceuticals	Neutral
GSK	Neutral

GSK has a consensus price target of GBX 2,048.57, indicating a potential upside of 6.78%. Given GSK's stronger consensus rating and higher probable upside, analysts clearly believe GSK is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

GSK has a net margin of 14.52% compared to Dechra Pharmaceuticals' net margin of -3.66%. GSK's return on equity of 28.35% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%
GSK	14.52%	28.35%	9.56%

Summary

GSK beats Dechra Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does GSK compare to Hikma Pharmaceuticals?

Hikma Pharmaceuticals (LON:HIK) and GSK (LON:GSK) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 56.9% of GSK shares are held by institutional investors. 22.0% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of GSK shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Hikma Pharmaceuticals has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, GSK has a beta of 0.295, suggesting that its stock price is 71% less volatile than the broader market.

GSK has a net margin of 14.52% compared to Hikma Pharmaceuticals' net margin of 11.31%. GSK's return on equity of 28.35% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	11.31%	15.05%	9.40%
GSK	14.52%	28.35%	9.56%

In the previous week, GSK had 4 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 5 mentions for GSK and 1 mentions for Hikma Pharmaceuticals. Hikma Pharmaceuticals' average media sentiment score of 0.75 beat GSK's score of 0.39 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hikma Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hikma Pharmaceuticals currently has a consensus target price of GBX 2,060, suggesting a potential upside of 25.92%. GSK has a consensus target price of GBX 2,048.57, suggesting a potential upside of 6.78%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Hikma Pharmaceuticals is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.1%. GSK pays an annual dividend of GBX 67 per share and has a dividend yield of 3.5%. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. GSK pays out 56.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.42B	1.00	£353.21M	£181.00	9.04
GSK	£33.20B	2.31	£2.50B	£117.80	16.29

Summary

Hikma Pharmaceuticals beats GSK on 10 of the 18 factors compared between the two stocks.

How does GSK compare to Indivior?

GSK (LON:GSK) and Indivior (LON:INDV) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

GSK has a net margin of 14.52% compared to Indivior's net margin of 11.44%. GSK's return on equity of 28.35% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.52%	28.35%	9.56%
Indivior	11.44%	-23.90%	2.37%

In the previous week, GSK had 4 more articles in the media than Indivior. MarketBeat recorded 5 mentions for GSK and 1 mentions for Indivior. Indivior's average media sentiment score of 0.75 beat GSK's score of 0.39 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	£33.20B	2.31	£2.50B	£117.80	16.29
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A

56.9% of GSK shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 0.2% of GSK shares are owned by company insiders. Comparatively, 3.4% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GSK pays an annual dividend of GBX 67 per share and has a dividend yield of 3.5%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. GSK pays out 56.9% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK currently has a consensus price target of GBX 2,048.57, indicating a potential upside of 6.78%. Given GSK's stronger consensus rating and higher possible upside, research analysts clearly believe GSK is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GSK has a beta of 0.295, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Summary

GSK beats Indivior on 14 of the 18 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GSK vs. The Competition

Export

Metric	GSK	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£76.93B	£12.57B	£7.37B	£2.54B
Dividend Yield	3.54%	2.61%	2.53%	6.17%
P/E Ratio	16.29	789.80	272.60	367.57
Price / Sales	2.31	764.53	624.33	83,481.74
Price / Cash	8.15	96.77	78.62	27.89
Price / Book	5.82	11.89	13.05	7.19
Net Income	£2.50B	£2.81B	£3.47B	£5.89B
7 Day Performance	3.81%	1.77%	2.09%	0.30%
1 Month Performance	0.68%	3.85%	6.64%	3.31%
1 Year Performance	29.67%	6.56%	25.02%	22.13%

GSK Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GSK GSK	2.7233 of 5 stars	GBX 1,918.50 -0.1%	GBX 2,048.57 +6.8%	+29.7%	£76.93B	£33.20B	16.29	70,212
AZN AstraZeneca	4.1041 of 5 stars	£122.40 +1.3%	£152.17 +24.3%	+2.3%	£189.83B	£61.37B	18.32	83,500	Analyst Forecast High Trading Volume
BMK Benchmark	N/A	£153 -0.6%	N/A	-12.6%	£94.15B	£79.16M	246,774.19	823	News Coverage
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
HIK Hikma Pharmaceuticals	4.5915 of 5 stars	GBX 1,636 +0.7%	GBX 2,060 +25.9%	-10.9%	£3.42B	£3.42B	9.04	9,100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:GSK) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Competitors